{
    "Question": "Ingrowth Biotech CES 2024 product highlight and specification",
    "Summary": "Ingrowth Biotech\n\nCES 2024\n\n- The Global Biotechnology Industry Outlook 2024 report highlights the anticipated performance of the biotech and biopharma sectors, covering advancements in gene editing technologies and the development of innovative therapies.\n\n- Key market players include prominent companies such as Thermo Fisher Scientific Inc., Danaher, Becton, Dickinson and Company, GE HealthCare, Agilent Technologies, Merck KGAA, Qiagen, Illumina, F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis, Merck & Co., Sanofi, Amgen, Gilead Sciences, Biogen, Bristol Myers Squibb, and GSK.\n\n- The cell and gene therapy market is expected to experience a remarkable >20% increase from 2023 to 2024, reaching approximately USD 11 billion, with a substantial influx of approvals and numerous clinical trials.\n\n- Other key trends for 2024 include the significant contributions of Artificial Intelligence (AI) in biotechnology, the transformative tool of gene editing, and the pivotal impact of leveraging big data in biotechnology.",
    "Summary_cn": "Ingrowth生物技术\n\nCES 2024\n\n-《2024年全球生物技术产业展望》报告重点关注生物技术和生物制药领域的预期业绩，涵盖基因编辑技术的进展和创新疗法的研发。\n\n- 关键市场参与者包括Thermo Fisher Scientific Inc.、Danaher、Becton Dickinson and Company、GE HealthCare、Agilent Technologies、默克KGAA、Qiagen、Illumina、F. Hoffmann-La Roche Ltd、辉瑞公司、诺华、Merck & Co.、赛诺菲、安进、吉利德科学、生物基因、百时美施贵宝和葛兰素史克等知名公司。\n\n- 细胞和基因疗法市场预计将在2023年至2024年间大幅增长20%，达到约110亿美元，审批和临床试验数量激增。\n\n- 2024年的其他主要趋势包括人工智能（AI）在生物技术中的重大贡献、基因编辑的转变性工具以及利用大数据在生物技术领域的重要影响。"
}